Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


ZIOPHARM Oncology Announces Dosing of First Patient in Phase 3 Study of ... 

 

ZIOPHARM Oncology Announces Dosing of First Patient in Phase 3 Study of ...
MarketWatch (press release)
Palifosfamide has demonstrated broad therapeutic activity, including effects against cancer stem cells, as well as good tolerability alone and in combination with various chemotherapeutics. MATISSE incorporates a novel, adaptive study design that ...

 

Posted on 13-Jun-12 by Toto, Brent
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: